{"commentary":{"count":45,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":29,"podcast":13,"x_thread":2,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06211764\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"SunRISe-5","nct_id":"NCT06211764","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=sunrise-5-nct06211764. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"SunRISe-5","arms":[{"description":"Participants will receive intravesical TAR-200 every 3 weeks during an induction phase and every 12 weeks during a maintenance phase.","label":"Group A: TAR-200","type":"EXPERIMENTAL"},{"description":"Participants will receive either single agent intravesical MMC or gemcitabine every week during an induction phase and every 4 weeks during a maintenance phase.","label":"Group B: Mitomycin C (MMC) or Gemcitabine","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2031-04-14","type":"ESTIMATED"},"conditions":["Non-Muscle Invasive Bladder Neoplasms"],"enrollment":{"count":272,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"TAR-200","type":"DRUG"},{"name":"Mitomycin C","type":"DRUG"},{"name":"Gemcitabine","type":"DRUG"}],"last_update":"2026-09-25","lead_sponsor":"Janssen Research & Development, LLC","official_title":"17000139BLC3004: 17000139BLC3004 [SunRISe-5] Ph III HR NMIBC BCG Exp/UR Pap (N=250)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2030-11-27","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease-free Survival (DFS)","timeFrame":"Up to 6 years 7 months"}],"references":[],"start_date":{"date":"2024-04-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)","url":"https://clinicaltrials.gov/study/NCT06211764"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/sunrise-5-nct06211764"}